Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Aug 17;82(3):428–437. doi: 10.1124/mol.112.077966

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

U.S. Government work not protected by U.S. copyright

PMC Copyright notice

Fig. 7. — A, Western blot indicating the expression level of Kv11.1-HA-WT and Kv11.1-HA-K887H in CHO cells treated with or without 200 pM PMA or 200 pM PMA + 10 μM PKC 20-28 or Kv11.1-HA-WT in CHO cells expressing shRNA targeting PKCα treated with 200 pM PMA + 10 μM PKC 20-28. B, Kv11.1-HA-WT and Kv11.1-HA-R887H protein expression is represented graphically upon treatment with 200 pM PMA or 200 pM PMA + 10 μM PKC 20-28 for 2 h. The chart shows the average total optical density of the channel band at 155 kDa from the densitometric analysis of immunoblots (IB) from three independent experiments expressed as percentage change of control. Data were normalized to Kv11.1-HA-WT expression levels present in cells (immunoprecipitates) with no drug added. C, representative immunoblot showing the total protein density of Kv11.1-HA-WT and Kv11.1-HA-R887H after treatment with 40 μM CHX for 0, 4, 8, and 24 h. β-Actin is used as an internal control. D, graphical representation of Kv11.1-HA-WT and Kv11.1-HA-R887H protein density after treatment with CHX. The chart shows the relative optical density of the hERG1 band at 155 kDa from the densitometric analysis of immunoblots from three independent experiments. The half-lives for Kv11.1-HA-WT and Kv11.1-HA-R887H were estimated to be 4.5 and 1.9 h. Data are means ± S.E. *, P < 0.05.